Neil Roskell - Concepedia

Author

Neil Roskell

Also Known As

N Roskell, N S Roskell, N. Roskell, N. S. Roskell, N.S. Roskell, Neil Roskell, Neil S Roskell, Neil S. Roskell, Neil S. Roskell

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation BresMed Bristol-Myers Squibb (United Kingdom)Institut Pasteur de Lille GlaxoSmithKline (United Kingdom)

About

Neil Roskell is an author at Research Triangle Park Foundation specializing in medicine, malaria, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	376
2	Public Health	3	3	143
3	Epidemiology	2	2	205
4	Health Sciences	1	1	26
5	Clinical Nutrition	1	1	26

Neil Roskell

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Atovaquone‐Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double‐Blind Study D. Overbosch, Herbert Schilthuis, Ulrich Bienzle, Clinical Infectious Diseases	2001	259
Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression Miranda Cooper, H. Kilvert, Paul Hodgkins, CNS Drugs	2019	191
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study Birthe Høgh, P D Clarke, Daniel Camus, The Lancet Malaria ProphylaxisMalariaParasite ControlAtovaquone-proguanil Versus Chloroquine-proguanilNon-immune Travellers	2000	147
Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study Annalisa Rubino, Neil Roskell, Pat Tennis, BMJ	2006	120
A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. T Y Sukwa, Modest Mulenga, N Chisdaka, American Journal of Tropical Medicine and Hygiene	1999	95
Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults Brian M. Sadler, Cynthia D. Hanson, Gregory E. Chittick, Antimicrobial Agents and Chemotherapy Hard Gelatin CapsulesProtease InhibitorTreatment And PreventionSoft Gelatin CapsulePharmacology	1999	66
A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy Teresa L. Kauf, Neil Roskell, Arran Shearer, Value in Health Modern EraPredictive ModelHealth System AnalysisHealthcare ProvisionHealth Policy	2008	59
Atovaquone-Proguanil versus Chloroquine-Proguanil for Malaria Prophylaxis in Nonimmune Pediatric Travelers: Results of an International, Randomized, Open-Label Study D. Camus, Félix Djossou, Herbert Schilthuis, Clinical Infectious Diseases Drug SafetyMalaria ProphylaxisMalariaPharmacologyPediatrics	2004	58
Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom Lia Gutiérrez, Neil Roskell, Jordi Castellsagué, Journal of Medical Economics	2011	38
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England Yang Meng, N. Hertel, J. Ellis, The European Journal of Health Economics	2018	30

Page 1